HomeCompareMFNC vs PFE

MFNC vs PFE: Dividend Comparison 2026

MFNC yields 51.61% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MFNC wins by $1952145.47M in total portfolio value
10 years
MFNC
MFNC
● Live price
51.61%
Share price
$21.50
Annual div
$11.10
5Y div CAGR
60%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1952145.52M
Annual income
$1,886,736,100,143.17
Full MFNC calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MFNC vs PFE

📍 MFNC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMFNCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MFNC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MFNC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MFNC
Annual income on $10K today (after 15% tax)
$4,386.60/yr
After 10yr DRIP, annual income (after tax)
$1,603,725,685,121.69/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MFNC beats the other by $1,603,725,662,801.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MFNC + PFE for your $10,000?

MFNC: 50%PFE: 50%
100% PFE50/50100% MFNC
Portfolio after 10yr
$976072.79M
Annual income
$943,368,063,200.95/yr
Blended yield
96.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MFNC
Analyst Ratings
2
Buy
Consensus: Buy
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MFNC buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMFNCPFE
Forward yield51.61%6.13%
Annual dividend / share$11.10$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR60%13.2%
Portfolio after 10y$1952145.52M$49.6K
Annual income after 10y$1,886,736,100,143.17$26,258.71
Total dividends collected$1947654.53M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: MFNC vs PFE ($10,000, DRIP)

YearMFNC PortfolioMFNC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$18,957$8,257.12$9,153$693.39+$9.8KMFNC
2$43,691$23,406.55$8,593$849.25+$35.1KMFNC
3$127,415$80,665.89$8,336$1,066.78+$119.1KMFNC
4$488,103$351,769.09$8,437$1,384.80+$479.7KMFNC
5$2,537,317$2,015,046.78$9,013$1,875.40+$2.53MMFNC
6$18,378,276$15,663,346.43$10,306$2,680.72+$18.37MMFNC
7$189,313,552$169,648,796.61$12,820$4,101.38+$189.30MMFNC
8$2,815,713,033$2,613,147,532.71$17,673$6,826.70+$2815.70MMFNC
9$61,130,299,352$58,117,486,407.20$27,543$12,591.86+$61130.27MMFNC
10$1,952,145,520,450$1,886,736,100,143.17$49,560$26,258.71+$1952145.47MMFNC

MFNC vs PFE: Complete Analysis 2026

MFNCStock

Mackinac Financial Corp. is a bank holding company, which engages in the provision of commercial banking services through its subsidiary, mBank. The company is headquartered in Manistique, Michigan and currently employs 294 full-time employees. The Company, through the Bank, is engaged in the general commercial banking business. The Bank provides a range of loan and deposit products. These banking services include customary retail and commercial banking services, including checking and savings accounts, time deposits, interest bearing transaction accounts, safe deposit facilities, real estate mortgage lending, commercial lending, commercial and governmental lease financing, and direct and indirect consumer financing. The funds for the Bank's operation are also provided by brokered deposits and through borrowings from the Federal Home Loan Bank (FHLB) system, proceeds from the sale of loans and mortgage-backed and other securities, funds from repayment of outstanding loans and earnings from operations. The Bank has over 13 branch offices located in the Upper Peninsula of Michigan and four branch offices located in Michigan's Lower Peninsula.

Full MFNC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MFNC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MFNC vs SCHDMFNC vs JEPIMFNC vs OMFNC vs KOMFNC vs MAINMFNC vs JNJMFNC vs MRKMFNC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.